TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01513278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APN201
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APN201
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
Study: NCT00362336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T
Description: 0.5 mL, Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CombAct-HIB®
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B® Pediatric
Description: 0.5 mL, IM
Study: NCT01553669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reminiscence therapy
Description: The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
Study: NCT04797546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Continous peripheral nerve block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Patient Controlled Analgesia
Description: Morphine Patient Controlled Analgesia Delivery System
Study: NCT00129545

Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN Left Atrial Appendage Closure Technology
Description: Implant of WATCHMAN Left Atrial Appendage Closure Technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Left Atrial Appendage Closure Technology
Description: Implant of WATCHMAN Left Atrial Appendage Closure Technology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Subjects receive warfarin
Study: NCT02413567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMR Procedure (Fractyl)
Description: Endoscopic procedure
Study: NCT03883984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate
Description: Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
Study: NCT00880594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum.
Study: NCT02575833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: A single dose of erenumab 140 mg infused over approximately 60 minutes.
Study: NCT03577028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 2 Prime Step IV 450 ng/kg Target
Description: Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPN424 Fixed SC
Description: Fixed subcutaneous dose 120 ng/kg
Study: NCT02575833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of a matching volume of placebo infused over approximately 60 minutes.
Study: NCT02732262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 1.00 mg dose
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.03 mg/kg dose
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.02 mg/kg dose
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
Study: NCT01171391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study: NCT03697824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3377794
Description: GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT01171391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on Day 1
Study: NCT01153360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liothyronine sodium
Description: liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: vitamin B12
Study: NCT01114438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Description: EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
Study: NCT03633266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: vitreoretinal surgery combined with intraoperative anti-VEGF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: vitreoretinal surgery combined with intraoperative PRP
Study: NCT01990612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Elective Induction of Labor
Description: Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
Study: NCT01887847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (Pharmaceutical Productions Inc.)
Description: An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (Pharmaceutical Productions Inc.)
Description: A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
Study: NCT03595527

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV and HCV screening
Description: HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
Study: NCT00006400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Participants will receive hydroxyurea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo.
Study: NCT01271374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine and olmesartan
Description: Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan and HCTZ
Description: Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
Study: NCT03634254

Intervention type: OTHER
Intervention: Satisfaction survey of communication quality:
Description: a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
Study: NCT03897855

Intervention type: OTHER
Group type: OTHER
Intervention: Post Traumatic Stress Disorder
Description: The test Think / No-Think

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Traumatic Stress Disorder
Description: The test Think / No-Think
Study: NCT03595488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab 300 mg subcutaneous injection every 2 weeks
Study: NCT03883984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered for 8 weeks. 125mg tablet QID.
Study: NCT00498069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harvest Smartprep2 BMAC System
Description: injection of 40cc bmac

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPReP2 BMAC System
Description: Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of placebo into ischemic tissue of the lower extremity
Study: NCT01619436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: bolus, clonidine 2 mg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer lactato
Description: 1 ML ringer lactato IV, as placebo
Study: NCT00396864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052
Description: NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
Study: NCT02561572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Yintang point acupuncture
Study: NCT04051320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: 3.75 mg/month leuprolide acetate intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: 3.75 mg/month leuprolide acetate intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 2 Mg tablet
Description: 2 mg estradiol tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 2 Mg tablet
Description: 2 mg estradiol tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: 200 mg micronized progesterone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: 200 mg micronized progesterone tablets
Study: NCT03723746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
Study: NCT00371904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care
Study: NCT02980133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol
Description: Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
Study: NCT03697824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT00808951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study: NCT02980133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Matching placebo was administered via MDPI per the schedule specified in the arm.
Study: NCT03208088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1
Study: NCT00808951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Study: NCT03208088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 2
Study: NCT03979755

Intervention type: OTHER
Intervention: Application of questionnaires
Description: Application of questionnaires described by telephone.
Study: NCT04247100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Active Transcutaneous Auricular Microstimulation delivered by TENS device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Active Transcutaneous Auricular Microstimulation delivered by TENS device
Study: NCT03208088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Test Lens 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens
Study: NCT04247100

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation
Description: Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
Study: NCT03208088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Investigational Toric Multifocal Contact Lens
Description: Control Lens
Study: NCT01997671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Support System
Description: Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
Study: NCT02277912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated rTMS of motor cortex
Description: Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated rTMS of somatosensory cortex 2
Description: Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM rTMS with SHAM block
Description: Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
Study: NCT02403232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCs injection
Description: In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASCs injection
Description: In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure of fistula tract.
Description: A SALVECOLL-E paste will be injected into the fistula tract.
Study: NCT02371031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection (standard of care)